Adrian L. Harris

发表

Consensus guidelines for the use and interpretation of angiogenesis assays

Robert J. Griffin, Federico Bussolino, Mark J. Post, 2018, Angiogenesis.

Machine learning to guide the use of adjuvant therapies for breast cancer

Mihaela van der Schaar, Ahmed M. Alaa, Jem Rashbass, 2020, Nature Machine Intelligence.

hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer

Carme Camps, Jiannis Ragoussis, Francesca M. Buffa, 2008, Clinical Cancer Research.

Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer

Manuela Milani, Stephen B. Fox, Adrian L. Harris, 2006, Clinical Cancer Research.

Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis

Paul J. Harrison, Peter J. Dobson, Bob Carr, 2011, Nanomedicine : nanotechnology, biology, and medicine.

Re: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma

Brian H. Mayall, Dan H. Moore, Stephen B. Fox, 1995 .

Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization

Jiannis Ragoussis, Benjamin A. Garcia, Francesca M. Buffa, 2011, Nature Medicine.

Association of hypoxia‐inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma

Adrian L. Harris, A. Harris, K. Gatter, 2002 .

bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer

Barbara Krammer, Adrian L. Harris, A. Harris, 2004, Clinical & Experimental Metastasis.

Comprehensive Proteomic Analysis of Breast Cancer Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical Cancer* 210

Pierre Legrain, Adrian L. Harris, A. Harris, 2003, The Journal of Biological Chemistry.

Targeting gene expression to hypoxic tumor cells

Adrian L. Harris, John D. Firth, A. Harris, 1997, Nature Medicine.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors

Jacob G. Scott, Francesca M. Buffa, Andrew Dhawan, 2018, Nature Communications.

Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer

Fergus Gleeson, John D. Fenwick, Fredrik Karpe, 2018, Cell metabolism.

Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER

Paul C. Boutros, Mircea Ivan, Francesca M. Buffa, 2014, Nature Communications.

Development of cancer metabolism as a therapeutic target: new pathways, patient studies, stratification and combination therapy

Adrian L. Harris, A. Harris, 2019, British Journal of Cancer.

Erratum: “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients,”

Giampietro Gasparini, Adrian L. Harris, A. Harris, 1993 .

A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

David J. Kerr, Eric Masson, Adrian L. Harris, 2005 .

MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU

Borivoj Vojnovic, Mircea Ivan, Jiannis Ragoussis, 2010, PloS one.

Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results

Marc Buyse, Mauro Delorenzi, Christos Sotiriou, 2005 .

Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?

Daniel F. Hayes, Adrian L. Harris, B. Trock, 2004, Breast Cancer Research and Treatment.

A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis

Demin Li, Francesca M. Buffa, Roger Patient, 2013, Cancer cell.

Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis

Luc Y. Dirix, Stephen B. Fox, Adrian L. Harris, 2005, Breast Cancer Research and Treatment.

Biological mechanisms that trigger breast cancer (BC) tumor progression are molecular subtype dependent

Gianluca Bontempi, Marc Buyse, Mauro Delorenzi, 2007 .

Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma

Patrick H. Maxwell, Adrian L. Harris, A. Harris, 2005, Molecular and Cellular Biology.

Hypoxia — a key regulatory factor in tumour growth

Adrian L. Harris, A. Harris, 2002, Nature Reviews Cancer.

Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures

Gianluca Bontempi, Marc Buyse, Mauro Delorenzi, 2006 .

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Relation of Hypoxia-inducible Factor-2α (HIF-2α) Expression in Tumor-infiltrative Macrophages to Tumor Angiogenesis and the Oxidative Thymidine Phosphorylase Pathway in Human Breast Cancer

Marian Taylor, Roy Bicknell, Adrian L. Harris, 2002 .

Regulation of tumor pH and the role of carbonic anhydrase 9

Richard D. Vaughan-Jones, Pawel Swietach, Adrian L. Harris, 2007, Cancer and Metastasis Reviews.